GSK at­tempts to re­make it­self in Chi­na with lo­cal ties

Glax­o­SmithK­line is ramp­ing up its R&D ef­forts in Chi­na af­ter a cou­ple of tu­mul­tuous years in the coun­try.

GSK’s Chi­na R&D Gen­er­al Man­ag­er Li Min told a re­cent fo­rum that the com­pa­ny has heav­i­ly in­vest­ed in neu­ro­science in Chi­na geared to­ward beef­ing up part­ner­ships with lo­cal uni­ver­si­ties un­der a five-year project dubbed Neu­ro 2020, Chi­na Dai­ly re­port­ed.

GSK has been in free fall in Chi­na af­ter bribery charges forced the com­pa­ny to pay near­ly $500 mil­lion in fines to re­solve those charges. The com­pa­ny sub­se­quent­ly cut about 40 per­cent of its sales force Chi­na in 2015, and it an­nounced that it would be over­haul­ing the way sales reps in Chi­na are com­pen­sat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.